Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dr Reddy’s Sees Revenue Growth Of 25 Percent This Financial Year, Improved Profitability

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - India's second biggest generic drug maker said it expects revenue growth of 25 percent in the financial year started April and gross margins of 50 percent led by improved cost control at its German betapharm unit and growing revenues from custom manufacturing and active pharmaceutical ingredient sales after earnings below expectations for the fourth quarter ended March

You may also be interested in...



Dr. Reddy’s Sees Profit Drop As Pricing Pressure Hits Generics Industry

MUMBAI - India's second largest drug maker Dr. Reddy's Laboratories posted a 26 percent drop in quarterly profit partly due to pricing pressures in the generics business

Dr. Reddy’s Sees Profit Drop As Pricing Pressure Hits Generics Industry

MUMBAI - India's second largest drug maker Dr. Reddy's Laboratories posted a 26 percent drop in quarterly profit partly due to pricing pressures in the generics business

PharmAsia News Notable Notes: India’s Sun, Dishman Price Targets Raised By Citigroup, Dr Reddy’s Maintained As Hold

NEW DELHI - Following fourth quarter earnings, Citigroup Global Markets hiked the price target for India's Sun and Dishman pharmaceutical companies citing strong and robust guidance and maintained a hold rating on Dr Reddy's saying management needed to present more clarity

Related Content

UsernamePublicRestriction

Register

SC068513

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel